Universal AAV Enhancer For Improved Viral Titers, Quality, And Reduced Production Costs
Source: Mirus Bio
AAV therapies require high quality and high titers of viral genomes per dosage, prompting the need for a more efficient AAV manufacturing method to reduce overall costs. The RevIT enhancer was created in response to this need with the potential to increase higher genome titers 2-4X in a range of suspension HEK 293 subtypes and cell culture media. Additional features allow you the flexibility to produce multiple AAV serotypes and, when paired with Mirus Bio's TransIT-VirusGen Transfection Reagent, enable complex stability in AAV manufacturing. Explore all the ways RevIT enhances your AAV production.
access the Poster!
Log In
Get unlimited access to:
Trend and Thought Leadership Articles
Case Studies & White Papers
Extensive Product Database
Members-Only Premium Content
Welcome Back! Please Log In to Continue.
X
Enter your credentials below to log in. Not yet a member of Bioprocess Online? Subscribe today.
Subscribe to Bioprocess Online
X
Subscribe to Bioprocess Online
Mirus Bio
This website uses cookies to ensure you get the best experience on our website. Learn more